For this reason, we considered the comprehensive data demonstrating that in AML patients an additional FLT3- ITD mutation is associated with a worse outcome compared with the expression of a single NPM1 mutation that can improve the prognosis in these patients [9,22]. This evidence concerns the gene FLT3 and acute myeloid leukemia.